PT  - JOURNAL ARTICLE
AU  - Lars Rönnblom
AU  - Dag Leonard
TI  - Interferon pathway in SLE: one key to unlocking the mystery of the disease
AID  - 10.1136/lupus-2018-000270
DP  - 2019 Aug 01
TA  - Lupus Science & Medicine
PG  - e000270
VI  - 6
IP  - 1
4099  - http://lupus.bmj.com/content/6/1/e000270.short
4100  - http://lupus.bmj.com/content/6/1/e000270.full
SO  - Lupus Sci Med Lupus Sci Med2019 Aug 01; 6
AB  - SLE is characterised by an activation of the interferon (IFN) system, which leads to an increased expression of IFN-regulated genes. The reasons behind the IFN signature in SLE are (1) the existence of endogenous IFN inducers, (2) activation of several IFN-producing cell types, (3) production of many different IFNs, (4) a genetic setup promoting IFN production and (5) deficient negative feedback mechanisms. The consequences for the immune system is a continuous stimulation to an immune response, and for the patient a number of different organ manifestations leading to typical symptoms for SLE. In the current review, we will present the existing knowledge of the IFN system and pathway activation in SLE. We will also discuss how this information can contribute to our understanding of both the aetiopathogenesis and some organ manifestations of the disease. We will put forward some issues that are unresolved and should be clarified in order to make a proper stratification of patients with SLE, which seems important when selecting a therapy aiming to downregulate the IFN system.